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More and more health-care authorities are turning to vaccines and vaccination to provide improved and affordable
protection against disease for both humans and animals. This is reflected in the renewed vigour with which established
pharmaceutical companies and the myriad of new biotech companies are vying with one another to come up with the
most active vaccine components and the methods for delivering them to people and animals. And vaccines have moved
into areas that were once the territory of drug treatments: cancer, allergy, addiction, arthritis, Alzheimer’s, contraception
and diabetes are now in the sights of researchers active in immunoprophylactic areas seeking to cure as well as protect.
So it is not surprising that some 450 attendees from 40 countries signed up to engage with 25 plenary talks, 54 oral
communications and 192 posters that were provided at this global congress organised by the Vaccine journal team of
Elsevier (www.vaccinecongress.com) working with the International Society for Vaccines (www.isv-online.org) .
This congress was also distinguished by providing part of its proceedings as a web cast so that some 1100 people
around the world signed on to take part in this virtual congress in addition to those attending in Boston. During these
sessions vaccinologists from many nations put their questions to the speakers via a web link and received the speakers’
response in real time. This material will also be available for the next three months at (www.vaccinecongress.com/virtual.htm).
Many speakers noted that the ‘low hanging vaccines’ had been picked by methods that are regarded as ‘empirical’.
That was the ‘logical or reasonable’ thing to do under the circumstances that prevailed in the past. Today we have at our
disposal a wide range of powerful tools to determine both the nature of the pathogen and to synthesise and formulate
materials that can be used prophylactically. Although it must also be noted that we really do not know enough about the
microbial agents that cause disease from the point of view of their physiology and the various strategies they deploy for
their survival. We are gradually coming to the determination that the antigens that are present at prominent positions on
the outer reaches of the organism express their function by causing the immune system to react in a manner that does not
cause the demise of the organism. So, we note that we have to bypass the ‘decoy’ antigens and re-engineer our strategies
to ignore these immunodominant sites and target our efforts on conserved sites that, when engaged by antibodies or
* Conference Co-Chair
Editor in Chief: Vaccine.
Series Editor in Chief; Procedia in Vaccinology.
E-mail: r.spier@surrey.ac.uk.
Procedia in Vaccinology 1 (2009) 1–3
Available online at www.sciencedirect.com
1877-282X © 2009 Published by Elsevier Ltd. 
doi:10.1016/j.provac.2009.07.001
2nd Vaccine Global Congress, Boston 2008
Open access under CC BY-NC-ND license.
2  Ray Spier / Procedia in Vaccinology 1 (2009) 1–3 
other effector agents, cause the death or disablement of the pathogenic organism. Examples of such approaches may be
seen in the papers that addressed the way vaccines are being designed and produced to protect against HIV/AIDS,
Influenza, Malaria, bacteria with polysaccharide capsules, Dengue and many others. Furthermore, modern vaccinologists
may be said to differ from their progenitors in that they are keen to develop vaccines that not only neutralise the disease-
causing organism of the day but also all the relatives of that organism. Thus we heard reports of the vaccines that would
cross-protect against the different clades of HIV, Dengue and Influenza Virus and with the latter virus the goal of
protecting against all the many subtypes of the virus should enable us in the first instance to make a vaccine that will
protect us against the threatening plague type of influenza (H5N1), as well as the other haemaglutinin and neuraminidase
variants that we use in our annual vaccinations. One vaccine should provide long-lasting protection against all such
viruses for many years, thus obviating the need for repeated annual vaccinations that are not popular.
The conferees were pleased to note that this congress provided them with opportunities to become more informed in
those areas of vaccinology that are other than the molecular basis of immunogenicity and clinical trials: although there
was ample information presented in these areas. In particular the question as to how it comes about that professionals in
medically sensitive areas (doctors, nurses, health-care providers generally) do not take up the influenza and
pneumococcal vaccines that are offered to them. Several speakers addressed this area and it became clear that such
individuals will take the vaccines only when required to do so as a condition of their employment in the hospital or in
general practice. Another study reported on health-care workers who refuse to be vaccinated against pertussis because,
amongst other reasons, they harbour a belief that such vaccines are not safe or will cause the disease that they are made to
protect against.
Because of a widespread dislike of needle delivered vaccines, two approaches to immunising people and animals were
gaining attention. These were nasal sprays or droplets and skin patches. Such methods of delivery require the adjuvants
that both activate the mucosal as well as the humoral immune responses. Additionally, much was made of the need to
stimulate both the cellular and antibody production sides of the immune response in virtually all the cases where we
have not yet achieved satisfactory and effective vaccines. To this end numerous papers presented data on new adjuvants
made from nanoparticles that are cationic as well as variants of the lipid/detergent/saponin liposomes that have the
ability to penetrate the skin when applied for some 6 hours under a local patch. In progressing these approaches methods
of storing vaccines for long periods without refrigeration have been developed. Such techniques depend on producing
‘sugar-like’ glasses using materials such as Trehalose or other mono- or di-saccharides. When dried these powders are
stable and can be delivered to chickens as dry powders to humans after reconstitution in buffer. This is not to neglect the
many other adjuvant systems that were described. These included the extracellular matrix derived from pig intestines,
the now acceptable MF59 oil in water emulsion and the efficacious CpG/interleukin-12 or 15 family of materials and the
formation of virus-like particles in different ways. These coupled with some new methods for organism inactivation
based on the use of hydrogen peroxide or inactivation by fusion have provided opportunities for new vaccine
compositions that are presently under active investigation. But this does not prevent the vaccinologists from looking
backwards and asking the question; how do the Alum-based vaccines that yet prevail in the human vaccine area work?
This opens up the subject of Toll-like-receptors and the various protein molecules that connect them with the genes that
express the cytokines and enzymes that carry the process of immunogenesis forward. However, the mechanism whereby
the solid surface of the alum particles activates the proteinaceous effector has yet to be discovered.
A spin-off in immune system manipulation is directed to the breaking down of self-tolerance. We heard papers that
showed that xenogeneic variants of antigens present at the surface of cancer cells could cause an antibody attack on such
antigens causing the death of the cancer cell. This has led to the production of a vaccine against dog melanoma based on
the DNA that codes for the human tyrosinase gene. This is the first licensed vaccine based on DNA. Other DNA vaccines
showed promise when they were presented as a DNA priming dose followed some weeks later by a booster dose of a
protein immunogen. Several workers presented such a regimen in their efforts to design an effective vaccine protective
against HIV/AIDS.
In terms of vaccine coverage one could discern a focus on the pneumococcal conjugate vaccines and vaccines
protective of the organisms that may be used in bio-warfare such as Lassa, Anthrax, Shigella, Staphylococcus, Fracisella,
Botulinum, Plague (Yersinia) and Ebola while much experimental work focused on the model viruses that cause
hepatitis such as HepB and HepC.
I conclude by reporting on two new methods that kept the light of this congress burning brightly. The first is a
method of imaging a virus in terms of its electrostatic charge profile. This enables the active elements of an attachment
or immunogenic site to be mapped and compared. Ultimately it was used to select immunogens for a vaccine to protect
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against Dengue virus. The second new method that caught my attention was a method that scaled up the PCR reaction
that produces copies of DNA molecules from a DNA primer. Here the PCR was effected in plastic tubes wrapped around
a central heating/cooling block so construed that some sections of the block were heated while others were cooled. Thus
in pumping the reactants through the tube they were subject to alternating cycles of heating and cooling. From this
prototype it is possible to get some 50mg DNA per day while a scaled-up version is envisaged that would yield 1gm per
day.
Of course, it is impossible to include all the viruses, vaccines and approaches in a short report; suffice it to note that
this conference reinforced where there was groundwork already in place and extended where extra dimensionality was
required. Its collegiate spirit enthused the participants and set the stage for future real and virtual congresses to take
vaccines and vaccination forward.
